IgA Vasculitis Market

Market Overview:

The 7 major IgA vasculitis markets reached a value of USD 579.9 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1,039.7 Million by ​2035​, exhibiting a growth rate (CAGR) of 5.48% during ​2025-2035​.

The IgA vasculitis market has been comprehensively analyzed in IMARC's new report titled "IgA Vasculitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ​2025-2035​". IgA (immunoglobulin A) vasculitis is a type of vasculitis characterized by inflammation of the blood vessels, which can limit blood flow and harm essential organs and tissues. IgA vasculitis inflames the small blood vessels of the skin, joints, intestines, and kidneys. It may occasionally impact the lungs and central nervous system. It is the most prevalent form of vasculitis in children. IgA vasculitis is systemic, which means it can affect several organ systems in the body. The most noticeable sign is a reddish skin rash that resembles bruises and primarily affects the legs and buttocks. Other common symptoms or signs of organ involvement are abdominal pain, joint pain and swelling, and renal inflammation. Individuals suffering from this ailment might experience nausea, vomiting, bloody stools, swelling of the testicles, seizures, fatigue, headaches, fever, etc. Diagnosing IgA vasculitis commonly involves a comprehensive evaluation of characteristic features, urinalysis, and blood tests. The healthcare provider may also perform a skin biopsy to examine tissue samples in patients for signs of vasculitis and IgA deposits.

The escalating prevalence of autoimmune disease, where the body's immune system mistakenly attacks its blood vessels, leading to inflammation and damage to the small blood vessels in the skin, joints, intestines, and kidneys, is primarily driving the IgA vasculitis market. In addition to this, the inflating utilization of nonsteroidal anti-inflammatory drugs (NSAIDs), like ibuprofen and naproxen, to help reduce joint pain and swelling, is also creating a positive outlook for the market. Moreover, the widespread adoption of plasma exchange procedures, which remove harmful circulating immune complexes and autoantibodies that contribute to inflammation and damage, is further bolstering the market growth. Apart from this, the rising usage of monoclonal antibody therapy, since it aims to target and reduce the activity of B cells, thereby preventing tissue damage, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of intravenous immunoglobulin (IVIg) on account of its several advantages, such as neutralized autoantibodies, improved renal function, and maintained remission, is expected to drive the IgA vasculitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the IgA vasculitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for IgA vasculitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the IgA vasculitis market in any manner.

Recent Developments:

• In January 2025, Vertex Pharmaceuticals Incorporated and Zai Lab Limited announced an exclusive collaboration and licensing agreement for the development and marketing of Vertex's povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan, and Singapore (the licensed territory).

Drugs:

Povetacicept, developed by Vertex Pharmaceuticals, acts by targeting B-cell activation and differentiation, crucial in IgA vasculitis pathogenesis. It works through inhibition of BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand), key regulators of B-cell survival and maturation. By blocking these signals, Povetacicept reduces the production of autoantibodies and inflammatory mediators implicated in IgA vasculitis, thereby mitigating immune system hyperactivity and tissue damage associated with the condition.

Avacopan, developed by ChemoCentryx and Vifor Fresenius Medical Care, is a selective C5a receptor antagonist that prevents complement system activation. In IgA vasculitis, increased C5a signaling causes neutrophil activation and vascular inflammation. By inhibiting the C5a receptor, Avacopan lowers neutrophil recruitment, inflammatory damage, and vascular injury without generally decreasing complement activity, providing a tailored approach to disease progression while limiting systemic immunosuppression.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: ​2025-2035​

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the IgA vasculitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the IgA vasculitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current IgA vasculitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the IgA vasculitis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the IgA vasculitis market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the IgA vasculitis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of IgA vasculitis across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of IgA vasculitis by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of IgA vasculitis by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with IgA vasculitis across the seven major markets?
• What is the size of the IgA vasculitis patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of IgA vasculitis?
• What will be the growth rate of patients across the seven major markets?

IgA Vasculitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for IgA vasculitis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the IgA vasculitis market?
• What are the key regulatory events related to the IgA vasculitis market?
• What is the structure of clinical trial landscape by status related to the IgA vasculitis market?
• What is the structure of clinical trial landscape by phase related to the IgA vasculitis market?
• What is the structure of clinical trial landscape by route of administration related to the IgA vasculitis market?